EADV 2022: Dupilumab Improves Itch, Skin Lesions in Prurigo Nodularis
Nearly 60 percent of patients treated with dupilumab experienced itch reduction at 24 weeks
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.